Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 2 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready
Kriya Therapeutics Inc. is managing 3 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are distributed among 3 distinct examiners, so each official is responsible for a single case. The portfolio spans 2 distinct art units, indicating some technical grouping within the company's biotechnology filings. This distribution of 3 pending actions across 3 distinct examiners requires the company to manage three separate examiner relationships simultaneously.
TIWARI, VYOMA SHUBHAM is the busiest examiner with 1 pending office action. With 3 pending actions and 2 art units, the company may encounter multiple examiners working within the same technical division. This structure requires a strategy that accounts for 3 distinct examiners across two administrative units. The concentration in 2 distinct art units is a significant factor, as it allows the company to monitor departmental trends that may affect the pending cases. Practitioners should focus on identifying the specific trends within the 2 distinct art units to better predict the behavior of the 3 distinct examiners. While each of the 3 pending office actions must be addressed individually, the departmental standards of the 2 art units will provide the necessary context for successful prosecution.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 3 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| TIWARI, VYOMA SHUBHAM | 1 | 31.5% | +48.1% |
| LARA, CAROLINE MONSERRAT | 1 | 100.0% | +0.0% |
| ALAM, DANYAL HASSAN | 1 | 66.7% | +0.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18861111 | INSULIN AND GLUCOKINASE GENE THERAPY COMPOSITIONS AND ITS USE FOR TREATING DIABETES | TIWARI, VYOMA SHUBHAM | — |
| 18548676 | VIRAL VECTOR CONSTRUCTS INCORPORATING DNA FOR INHIBITING TOLL LIKE RECEPTORS AND METHODS OF USING THE SAME | LARA, CAROLINE MONSERRAT | — |
| 18262880 | VECTOR CONSTRUCTS FOR DELIVERY OF NUCLEIC ACIDS ENCODING THERAPEUTIC ANTI-TNF ANTIBODIES AND METHODS OF USING THE SAME | ALAM, DANYAL HASSAN | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18861111 | INSULIN AND GLUCOKINASE GENE THERAPY COMPOSITIONS AND ITS USE FOR TREATING DIABETES | TIWARI, VYOMA SHUBHAM | — |
| Art Unit | Apps |
|---|---|
| 1633 | 2 |
| 1672 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18861111 | INSULIN AND GLUCOKINASE GENE THERAPY COMPOSITIONS AND ITS USE FOR TREATING DIABETES | TIWARI, VYOMA SHUBHAM | 1633 | §103§112Other | Non-Final OA | — | Pending | Oct 28, 2024 |
| 18548676 | VIRAL VECTOR CONSTRUCTS INCORPORATING DNA FOR INHIBITING TOLL LIKE RECEPTORS AND METHODS OF USING THE SAME | LARA, CAROLINE MONSERRAT | 1633 | §102§103 | Non-Final OA | — | Pending | Sep 01, 2023 |
| 18262880 | VECTOR CONSTRUCTS FOR DELIVERY OF NUCLEIC ACIDS ENCODING THERAPEUTIC ANTI-TNF ANTIBODIES AND METHODS OF USING THE SAME | ALAM, DANYAL HASSAN | 1672 | §103§112 | Non-Final OA | — | Pending | Jul 25, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial